Lawyer for Parexel Drug Trial Victims Welcomes Duff Report and Urges Government to Respond Speedily
07/12/2006
We found you very professional as well as approachable, helpful and caring. We can now move on and look forward to a more stable and secure future. I am sure that this would not have happened without yourselves being involved.
Jayne, Evesham
Drug trials went disastrously wrong
The lawyer representing
three of the seven victims of the TGN1412 clinical drug trials, that
went disastrously wrong in March 2006, has welcomed today's report by
Professor Gordon Duff. However law firm Irwin Mitchell (incorporating
Alexander Harris) has called for a more far reaching independent
enquiry to be instigated describing today's report as "not having the
wide remit needed to allow the full story to be heard, and all the
lessons to be learnt."
Seriously injured in the TGN1412 trial
Irwin
Mitchell, the law firm representing Ryan Wilson and Mohamed Abdelhady,
the two men most seriously injured in the TGN1412 trial as well as
Raste Khan who was given the placebo as part of the trial, said: "We
very much appreciate the opportunity that volunteers were given to
express their concerns, and although much of what was discussed was
beyond the group's remit they have recognised the importance of the
volunteers' contribution and have recommended that these wider concerns
be taken up as a high priority."
"We also welcome the finding
that the pre clinical development studies that were performed with TGN
1412 did not predict a safe dose for use in humans even though current
regulatory requirements were met. Going forward it is now critical that
the 22 recommendations made by the committee are implemented urgently
to ensure the safety, rights and well-being of volunteers taking part
in future clinical trials."
The Expert Scientific Group (ESG),
chaired by Professor Gordon Duff was commissioned by the Secretary of
State for Health following six men's adverse reactions to the drug
TGN1412. The drug trial took place at a unit run by drug testing
company Parexel, attached to Northwick Park Hospital, in March 2006.
Safety of phase 1 drug trials
The
ESG was set up to look at how to improve the safety of phase 1 clinical
drug trials. Its interim report was published in July this year;
today's final report follows a wide ranging consultation with victims,
doctors and other experts on the group's initial findings.
Back to news
If you would like us to provide you with advice with regard to your potential claim, please complete our brief claim form. We will reply to your enquiry within one working day.
Fill out our quick claim form
If you would like to speak to someone directly about your claim, please call our friendly team on:
0870 024 0558